The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis
Authors
Keywords
-
Journal
Expert Review of Clinical Immunology
Volume 10, Issue 8, Pages 981-983
Publisher
Informa UK Limited
Online
2014-06-25
DOI
10.1586/1744666x.2014.932690
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
- (2014) Jackie L Nam et al. ANNALS OF THE RHEUMATIC DISEASES
- A Review of CT-P13: An Infliximab Biosimilar
- (2014) Kate McKeage BIODRUGS
- Biosimilars in rheumatology: the wind of change
- (2013) Christian K Schneider ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
- (2013) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
- (2013) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Inequities in access to biologic and synthetic DMARDs across 46 European countries
- (2013) Polina Putrik et al. ANNALS OF THE RHEUMATIC DISEASES
- Biosimilars in IBD: hope or expectation?: Table 1
- (2013) Krisztina B Gecse et al. GUT
- Approval of the first biosimilar antibodies in Europe
- (2013) Alain Beck et al. mAbs
- The INN crowd
- (2013) NATURE BIOTECHNOLOGY
- Analytical characterization of biosimilar antibodies and Fc-fusion proteins
- (2013) Alain Beck et al. TRAC-TRENDS IN ANALYTICAL CHEMISTRY
- Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions
- (2013) Jose Ramon Maneiro et al. JAMA Internal Medicine
- Characterization of Therapeutic Antibodies and Related Products
- (2012) Alain Beck et al. ANALYTICAL CHEMISTRY
- The role of biosimilars in the treatment of rheumatic diseases
- (2012) Thomas Dörner et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial
- (2012) Larry W. Moreland et al. ARTHRITIS AND RHEUMATISM
- The safety of switching between therapeutic proteins
- (2012) Hans C Ebbers et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
- (2012) Ronald F van Vollenhoven et al. LANCET
- The advent of biosimilar therapies in rheumatology—“O Brave New World”
- (2012) Morton A. Scheinberg et al. Nature Reviews Rheumatology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started